Ghrelin, a recently discovered peptide in the mammalian hypothalamus and gastrointestinal tract is thought to be the endogenous ligand for the GH secretagogue (GHS) receptor and it stimulates GH release in rats and humans. The possibility that ghrelin is present in birds was therefore assessed, since a GHS receptor is present in the chicken pituitary gland. Although immunoreactive ghrelin is readily detectable in the rat stomach and ileum, ghrelin immunoreactivity could not be detected in the chicken proventriculus, stomach, ileum or colon, whereas somatostatin immunoreactivity, in contrast and as expected, was readily detectable in the chicken gastrointestinal tract. Ghrelin immunoreactivity was, however, present in the chicken hypothalamus, although not in the arcuate (infundibular) nucleus, as in rats. Discrete parvocellular cells and neuronal fibers with ghrelin immunoreactivity were present in the anterior medial hypothalamus. This immunoreactivity was specific and completely abolished following the preabsorption of the antibody with an excess of human ghrelin. Ghrelin immunoreactivity was also present in clusters of large ovoid magnocellular cells in the nucleus magnocellularis preopticus pars medialis, nucleus magnocellularis preopticus supraopticus and in the chiasmaopticus. Immunoreactivity for ghrelin was restricted to the cytoplasm of the perikarya and their axonal sprouts. Immunoreactivity for ghrelin was not seen in any other hypothalamic nuclei. In a preliminary experiment, circulating GH concentrations in conscious immature chicks were promptly increased following bolus i.v. administration of human ghrelin. The increase in GH concentration (approximately three times that in the controls) was comparable with that induced by the same dose (10 microg/kg) of human GH-releasing hormone, although less than that (approximately sixfold) induced by thyrotropin-releasing hormone. These results demonstrate the presence of a ghrelin-like protein in the chicken hypothalamus and suggest that it participates in the regulation of GH secretion in birds.

Growth hormone (GH) gene expression predominantly occurs in the pituitary gland, although it also occurs in many extrapituitary sites, including the brain. The cellular location and ontogeny of neural GH production is, however, largely unknown. This has therefore been determined during chick embryogenesis. In chicks, the brain develops from the neural tube at embryonic day (ED) 3. At this age, the divisions of the brain (the telencephalon, diencephalon, mesencephalon, metencephalon and myelencephalon) have intense GH immunoreactivity (GH-IR) (detected by two polyclonal antibodies and a monoclonal antibody for chicken GH). The otic and optic vesicles were also strongly GH immunoreactive, as were the Vth (semi-lunar), VIIth (facial), VIIIth (acoustic) and IXth (glossopharyngeal) nerve ganglia. This GH-IR was specific for GH and was lost when the antibodies were preabsorbed with recombinant chicken GH. The widespread distribution of GH-IR in the neural tissues of ED 3 embryos was mirrored by the distribution of GH receptor (GHR) immunoreactivity, detected by an antibody raised against the chicken GHR. In ED 6/ED 7 embryos, the neural retina of the eye and the epithelial and lens fiber cells were intensely stained for GH-IR, as was Rathke's pouch and the wall of the diencephalon. In contrast, only a few scattered cells were immunoreactive in the surrounding mesoderm. At ED 14, the GH-IR in the brain was restricted to specific tissues and cells. For instance, immunoreactive cells were present in the molecular and pyramidal layers of the cerebral cortex, in the gray matter of the cerebellum, in the choroid plexus, and in the walls of the ventricles. In summary, GH- and GHR-like proteins are abundant in neural tissues of the chick during the first third of incubation, becoming discretely localized to specific tissues and cells during later incubation. The localization of GH and GHR in these tissues, prior to the ontogeny of plasma GH, suggests autocrine or paracrine roles for GH during early embryogenesis.

This brief review of the neurological effects of growth hormone (GH) and gonadotropin-releasing hormone (GnRH) in the brain, particularly in the cerebral cortex, hypothalamus, hippocampus, cerebellum, spinal cord, neural retina, and brain tumors, summarizes recent information about their therapeutic potential as treatments for different neuropathologies and neurodegenerative processes. The effect of GH and GnRH (by independent administration) has been associated with beneficial impacts in patients with brain trauma and spinal cord injuries. Both GH and GnRH have demonstrated potent neurotrophic, neuroprotective, and neuroregenerative action. Positive behavioral and cognitive effects are also associated with GH and GnRH administration. Increasing evidence suggests the possibility of a multifactorial therapy that includes both GH and GnRH.

Postnatally, endocrine GH is primarily produced by pituitary somatotrophs. GH is, however, also produced in extrapituitary sites, including tissues of the developing nervous system such as the neural retina. Whereas GH roles in the nervous system are starting to emerge, they are still largely unknown. We show here that GH in the neural retina is mainly present in the axons of retinal ganglion cells (RGCs) in embryonic day (E) 4–12 chick embryos, but it is no longer present at E14–18. This temporal window corresponds to the period of RGC axon growth. GH receptor mRNA was also detected within cells of the E7 RGC layer and GH receptor protein colocalized with GH in RGC axons. The possibility that GH promotes axon growth was thus investigated. Exogenous GH induced a significant increase in axon elongation at 10⁻⁹ and 10⁻⁶m in E7 RGC culture purified by immunopanning. RNA interference-mediated gene silencing was used to examine whether endogenous GH similarly alters axon outgrowth. The ability of GH small-interfering RNA to knock down GH was first tested using HEK cells on a LacZ-cGH expression plasmid and found to reach 90%. Upon transfection of GH small-interfering RNA to immunopanned RGC culture, a 63% knockdown of endogenous GH was detected and RGC axon length was found to be reduced by 40%. Taken together, these data suggest that GH acts as an autocrine or paracrine signaling molecule to promote axon growth in a developing nervous tissue, the neural retina of chick embryos.